LULU vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 13, 2026

LULU

37.2
AI Score
VS
MRNA Wins

MRNA

39.1
AI Score

Investment Advisor Scores

LULU

37score
Recommendation
SELL

MRNA

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric LULU MRNA Winner
Revenue 4.89B 534.00M LULU
Net Income 524.27M -2.13B LULU
Net Margin 10.7% -397.9% LULU
Operating Income 730.60M -2.20B LULU
ROE 10.9% -31.4% LULU
ROA 6.2% -19.4% LULU
Total Assets 8.48B 10.96B MRNA
Current Ratio 2.19 2.29 MRNA
Free Cash Flow 312.22M -1.25B LULU

Relative Price Performance (Last 90 Days)

LULU 1M: -18.1% · 3M: -18.8% MRNA 1M: +126.1% · 3M: +190.0%

Current Technical Phase

LULU

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.6%), weak momentum, RSI 34

RSI (14): 33.9 · Price: $98.97

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (50.4% over 20 days), RSI 61

RSI (14): 61.3 · Price: $143.97

Fundamentals Snapshot

Metric LULU MRNA
Market Cap
Forward P/E 7.9 -29.2
Trailing P/E 8.2
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 0.5% -0.7%
Operating Margin 0.1% -5.6%
EPS 11.80 -8.03
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.